Recent Updates
Recently added Catalysts

Travoprost Intracameral exchanged at Month 12

Phase 2

Glaucoma, Open-Angle | Small molecule | Ophthalmology |Glaukos Corporation|Last Updated: Oct 15, 2024

Target and mechanism

ModalitySmall molecule

Also known as Travoprost Intracameral Implant exchanged at Month 12

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment210

FDA Designations

No designations recorded

Clinical trial landscape

Travoprost Intracameral exchanged at Month 12 · 1 trial · 2 indications

Phase 2 1
NCT06582732Performance of the Travoprost Intraocular ImplantGlaucoma, Open-Angle
COMPLETED210 Analytics
PHASE2COMPLETED
Performance of the Travoprost Intraocular Implant
Glaucoma, Open-AngleUnlock trial analytics

Study Endpoints

Primary Endpoints

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration
month 12

concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration
month 3

concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration
month 6

concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration
month 24

concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS

Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration
month 21

concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration
month 18

concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS

Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration
month 15

concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS

Secondary Endpoints

Percent Residual Travoprost in Explanted Implant 12 Months Post-administration
month 12
Percent Residual Travoprost in Explanted Implant 3 Months Post-administration
month 3
Percent Residual Travoprost in Explanted Implant 6 Months Post-administration
month 6
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1 (12-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 12
Cohort 2 (3-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 3
Cohort 3 (6-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 6
Cohort 4 (24-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 24
Cohort 5 (21-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 21
Cohort 6 (18-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 18
Cohort 7 (15-month exchange)EXPERIMENTALTravoprost Intracameral Implant Exchanged at Month 15

Interventions

NameTypeDescription
Travoprost Intracameral Implant exchanged at Month 12DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
Travoprost Intracameral Implant exchanged at Month 3DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
Travoprost Intracameral Implant exchanged at Month 6DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
Travoprost Intracameral Implant exchanged at Month 24DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
Travoprost intracameral implant exchanged at Month 21DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
Travoprost intracameral implant exchanged at Month 18DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
Travoprost intracameral implant exchanged at Month 15DRUGintracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Diagnosis of either open angle glaucoma (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or ocular hypertenson * Zero to three topical intraocular pressure lowering medications at the time of Visit 1 (Screening) exam. * Best spectacle corrected visual acuity of 16 let...

Countries:Armenia
Unlock Eligibility Criteria